Paul-Peter Tak
CEO & Board Director

Paul Peter Tak

Paul Peter Tak is a business leader, academic, entrepreneur and clinician who has over 30 years’ experience in medicine as a prominent expert in Immunology, Internal Medicine, and Rheumatology. Paul Peter is currently the President, CEO, and Board Director of Candel Therapeutics, the Co-Founder and Board Director of Sitryx Therapeutics, and Board Director of Levicept and Citryll.

Alongside his industry career, Paul Peter has dedicated much of his life to academia and advancing our understanding in medicine. He has served as Professor of Medicine at the University of Amsterdam and holds numerous honours for his service to medicine, with a special focus on Immunology and Rheumatology.

Looking forward to seeing many friends and colleagues at ABI2024 in Cambridge!
Accelerating Bio-Innovation Conference | Royalty Pharma

We are pleased to share that CAN-2409 has received Orphan Drug Designation to treat pancreatic cancer.
CAN-2409 has demonstrated the ability to significantly extend survival in pancreatic cancer patients and potentially change the treatment landscape.

https://ir.candeltx.com/news-releases/news-release-details/candel-therapeutics-receives-fda-orphan-drug-designation-can

Today we announce that Candel Therapeutics received FDA Orphan Drug Designation for CAN-2409 for the treatment of pancreatic cancer. The FDA has granted Candel with both Orphan Drug and Fast Track Designation, as we seek to reshape the treatment paradigm in this disease. $CADL

The Power List 2024: Thank you, audience of The Medicine Maker. A big surprise and honor to be on the list with 29 influential and inspirational colleagues.
⁦@CandelTx⁩

Load More
Paul Peter Tak

© Paul Peter Tak.
All rights reserved.